Results 11 to 20 of about 16,055,883 (292)
Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies. [PDF]
Ibuprofen is the most commonly used NSAID; however, its short biological half‐life, reflected in the short duration of pain relief, limits the comfortableness of its usage. This study evaluated the pharmacokinetic properties of a newly developed biphasic
Kvapilová L +6 more
europepmc +2 more sources
A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants. [PDF]
BackgroundThis research aimed to compare the bioequivalence of a test formulation (regorafenib produced by Beijing SL Pharmaceutical Co., Ltd.) with a reference formulation (the original drug Stivarga®) in Chinese healthy subjects under fasting ...
Li Y, Qi L, Yang C, Zhao N, Wang X.
europepmc +2 more sources
Consideration on Food Effect Studies for Anticancer Drugs Approved in Japan Between 2001 and 2022. [PDF]
In developing a new drug, studies to evaluate the food effect (FE) on the drug's pharmacokinetics (FE studies) are generally conducted in healthy subjects in the early stages of clinical development.
Shibuya M, Kubota H, Maeda H.
europepmc +2 more sources
Food Effect and Formulation: How Soluble Fillers Affect the Disintegration and Dissolution of Tablets in Viscous Simulated Fed State Media. [PDF]
The food-induced viscosity of the media can alter tablet disintegration and eventually the release of the drug it contains. The extent of this retardation depends on tablet formulation factors, such as the solubility of its excipients.
Umer MF +8 more
europepmc +2 more sources
Diets, Foods and Food Components’ Effect on Dyslipidemia [PDF]
Hypercholesterolemia is a well-known independent risk factor for cardiovascular disease and a recognized target of pharmacological therapeutic agents in both primary and secondary prevention [...]
Federica Fogacci +2 more
openaire +2 more sources
Background: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC).
Jia Xu +9 more
doaj +1 more source
Background: Ursodeoxycholic acid (UDCA) is a natural drug essential for the treatment of cholestatic liver diseases. The food effects on the absorption of UDCA and the disposition of circulating bile salts remain unclear despite its widespread global ...
Liang Huang +15 more
doaj +1 more source
BackgroundGolidocitinib is an orally available, potent and highly selective JAK (Janus kinase)-1 inhibitor of JAK/STAT3 signaling under clinical development for the treatment of cancer and autoimmune diseases.
Kan Chen +11 more
doaj +1 more source
The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned.
Dénes Csonka +6 more
doaj +1 more source
HSK16149 is a novel, potent gamma‐aminobutyric acid (GABA) analog for the treatment of neuropathic pain. The purpose of this study was to assess the effect of a high‐fat and high‐calorie meal on the pharmacokinetics of HSK16149 in healthy Chinese ...
Qingqing Wu +9 more
doaj +1 more source

